Global Alzheimer’s Therapeutics Market is Expected to Reach USD 8.19 Billion By 2026 : Fior Markets
09. Juli 2019 07:57 ET
|
Fior Markets
New Jersey, NJ, July 09, 2019 (GLOBE NEWSWIRE) -- Fior Markets launched a study titled "Alzheimer’s Therapeutics Market by Drug Type (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor...
Alzheimer’s Therapeutics Market to Reach USD 12.43 Billion By 2026 | Reports And Data
02. Mai 2019 12:00 ET
|
Reports And Data
Rising incidence of investment in biomarkers for drug development is the major factor influencing market growth. Market Size – USD 18.23 billion in 2018, Market Growth - CAGR of 4.6%, Market Trends...
Otonomy to Report Second Quarter 2018 Financial Results and Provide Corporate Update
01. August 2018 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...
Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO® in Patients with History of Otitis Media Requiring Tympanostomy Tubes
15. September 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Ménière’s Disease Patients
01. August 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Report Second Quarter 2016 Financial Results and Provide Corporate Update
28. Juli 2016 16:30 ET
|
Otonomy, Inc.
SAN DIEGO, July 28, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Reports First Quarter 2016 Financial Results and Provides Corporate Update
09. Mai 2016 16:15 ET
|
Otonomy, Inc.
SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Present at the Bank of America Merrill Lynch Healthcare Conference
05. Mai 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 05, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière’s Disease
23. März 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 23, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Announces Publication of OTIPRIO™ Phase 3 Clinical Trial Results in JAMA Otolaryngology
18. März 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 18, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...